Drugs / Cosyntropin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CORTROSYN | — | 1970-04-22 | fda.gov ↗ |
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04546126 | Nov 2021 → Dec 2026 expected | hypertensive disorder | Benjamin Viglianti | Recruiting | No outcome recorded |
| Phase 0 | NCT04037605 | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03709381 | Oct 2017 → Oct 2018 | adrenocortical insufficiency, osteoporosis | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03142893 | May 2017 → Oct 2020 overdue | — | Peter y. Liu | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01673087 | Oct 2012 → Aug 2017 | — | University of Michigan | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03347526 | Apr 2018 → Jun 2021 | infantile spasms | University of Colorado, Denver | Suspended | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03752190 | Jul 2019 → Sep 2020 | adrenocortical insufficiency | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02394457 | Aug 2010 → Apr 2014 | headache disorder | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01764711 | Jan 2013 → Dec 2020 | postural orthostatic tachycardia syndrome | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01421797 | Oct 2006 → Aug 2024 | obesity disorder, polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01422733 Background | Jun → Jul 2018 | obesity disorder, polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01839812 Background | Mar 2009 → Jun 2013 | adrenal cortex disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03368066 Background | Jan 2018 → Mar 2019 | LCAT deficiency, adrenocortical insufficiency, anemia, nonspherocytic hemolytic, cirrhosis of liver | University of Virginia | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02339506 Comparator | Apr 2015 → Oct 2016 | baroreflex failure | Brigham and Women's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cosyntropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04037605 ↗ |
| Known as | ACTH | “Cosyntropin (synthetic ACTH) stimulation test” NCT03752190 ↗ |
| Known as | Cortrosyn | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01421797 ↗ |
| Route | Intravenous | “Cortrosyn given single IV bolus 0f 0.25 mg” NCT01421797 ↗ |